Memantine and Donepezil Capsules and Tofacitinib Extended-Release Tablets
Determining the interaction of Memantine and Donepezil Capsules and Tofacitinib Extended-Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Tofacitinib has been shown to decrease heart rate and prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta-blockers, digoxin, alpha-2 adrenoceptor agonists) may result in elevated risk of conduction disturbances and atrioventricular block. In clinical trials, use of tofacitinib (10 to 20 mg daily; at steady-state) was associated with significant decreases in heart rate (4 to 7 bpm) and increases in PR interval (4 to 10 ms) compared with placebo. MANAGEMENT: According to the manufacturer, concomitant use of tofacitinib with other agents that lower heart rate and/or prolong the PR interval should be avoided when possible. Caution is advised if concomitant use is necessary, particularly in patients with known conduction problems or severe cardiac disease. An ECG should be considered in these patients before initiating concomitant therapy and after titration to steady-state. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeats. References Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink." Cerner Multum, Inc. "Australian Product Information." O 0
Professional:GENERALLY AVOID: Tofacitinib has been shown to decrease heart rate and prolong the PR interval of the electrocardiogram in some patients. Theoretically, coadministration with other agents that prolong the PR interval (e.g., beta-blockers, digoxin, alpha-2 adrenoceptor agonists) may result in elevated risk of conduction disturbances and atrioventricular block. In clinical trials, use of tofacitinib (10 to 20 mg daily; at steady-state) was associated with significant decreases in heart rate (4 to 7 bpm) and increases in PR interval (4 to 10 ms) compared with placebo.
MANAGEMENT: According to the manufacturer, concomitant use of tofacitinib with other agents that lower heart rate and/or prolong the PR interval should be avoided when possible. Caution is advised if concomitant use is necessary, particularly in patients with known conduction problems or severe cardiac disease. An ECG should be considered in these patients before initiating concomitant therapy and after titration to steady-state. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeats.
- Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: donepezil / memantine
Brand name: Namzaric, Namzaric Titration Pack
Synonyms: Donepezil and memantine, Memantine and Donepezil
Generic Name: tofacitinib
Brand name: Xeljanz, Xeljanz XR
Synonyms: Tofacitinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Memantine and Donepezil Capsules-Tofacitinib Tablets
- Memantine and Donepezil Capsules-Tofranil
- Memantine and Donepezil Capsules-Tofranil injection
- Memantine and Donepezil Capsules-Tofranil-PM
- Memantine and Donepezil Capsules-Tol-Tab
- Memantine and Donepezil Capsules-Tolazamide
- Tofacitinib Extended-Release Tablets-Memantine ER capsules
- Tofacitinib Extended-Release Tablets-Memantine ER Tablets
- Tofacitinib Extended-Release Tablets-Memantine Extended-Release Capsules
- Tofacitinib Extended-Release Tablets-Memantine Hydrochloride
- Tofacitinib Extended-Release Tablets-Memantine Oral Solution
- Tofacitinib Extended-Release Tablets-Memantine Solution